BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38350047)

  • 41. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis.
    Quhal F; Mori K; Sari Motlagh R; Laukhtina E; Pradere B; Rouprêt M; Necchi A; Moschini M; Shariat SF
    Int J Clin Oncol; 2020 Jun; 25(6):1037-1054. PubMed ID: 32206939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic Value of Albumin/Globulin Ratio in Patients with Upper Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy.
    Fukushima H; Kobayashi M; Kawano K; Morimoto S
    Anticancer Res; 2018 Apr; 38(4):2329-2334. PubMed ID: 29599356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extraurothelial recurrence after radical nephroureterectomy: preoperative predictors and survival.
    Dzamic Z; Milojevic B; Kajmakovic B; Grozdic Milojevic I; Bojanic N; Sipetic Grujicic S
    Int Urol Nephrol; 2015 May; 47(5):775-9. PubMed ID: 25772384
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: updated results of the Seoul National University Hospital experience.
    Kim HS; Lee JS; Jeong CW; Kwak C; Kim HH; Ku JH
    Int Braz J Urol; 2015; 41(6):1067-79. PubMed ID: 26742963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pattern and risk factors of local recurrence after nephroureterectomy for upper tract urothelial carcinoma.
    Li X; Cui M; Gu X; Fang D; Li H; Qin S; Yang K; Zhu T; Li X; Zhou L; Gao XS; Wang D
    World J Surg Oncol; 2020 May; 18(1):114. PubMed ID: 32473636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?
    Favaretto RL; Shariat SF; Chade DC; Godoy G; Kaag M; Cronin AM; Bochner BH; Coleman J; Dalbagni G
    Eur Urol; 2010 Nov; 58(5):645-51. PubMed ID: 20724065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment Patterns, Outcomes, and Costs Associated With Localized Upper Tract Urothelial Carcinoma.
    Fero KE; Shan Y; Lec PM; Sharma V; Srinivasan A; Movva G; Baillargeon J; Chamie K; Williams SB
    JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34805743
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
    J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Postoperative and Survival Outcomes After Cytoreductive Surgery in the Treatment of Metastatic Upper Tract Urothelial Carcinoma.
    Pollock G; Hsu CH; Batai K; Lee BR; Chipollini J
    Urology; 2021 Jul; 153():244-249. PubMed ID: 33482133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of concomitant variant histology on the prognosis of patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy.
    Shibing Y; Turun S; Qiang W; Junhao L; Haichao Y; Shengqiang Q; Ping H; Dehong C
    Urol Oncol; 2015 May; 33(5):204.e9-16. PubMed ID: 25800374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concomitant carcinoma in situ as a prognostic factor in the upper tract urothelial carcinoma after radical nephroureterectomy: A systematic review and meta-analysis.
    Gao X; Ma Y; Chen G; Chen J; Li H; Li H; Wei X; Wang K
    Urol Oncol; 2020 Jun; 38(6):574-581. PubMed ID: 32273049
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
    Thalmann GN; Markwalder R; Walter B; Studer UE
    J Urol; 2002 Oct; 168(4 Pt 1):1381-5. PubMed ID: 12352398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
    Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Kosaka T; Mizuno R; Mikami S; Kikuchi E; Oya M
    Cancer Sci; 2021 Mar; 112(3):1084-1094. PubMed ID: 33368857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy.
    Yeh HC; Margulis V; Singla N; Hernandez E; Panwar V; Woldu SL; Karam JA; Wood CG; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Li CC; Ke HL; Li WM; Lee HY; Rapoport LM; Lotan Y; Kapur P; Shariat SF; Hsieh JT; Wu WJ
    Urol Oncol; 2020 May; 38(5):496-505. PubMed ID: 31862213
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience.
    Cutress ML; Stewart GD; Tudor EC; Egong EA; Wells-Cole S; Phipps S; Thomas BG; Riddick AC; McNeill SA; Tolley DA
    J Urol; 2013 Jun; 189(6):2054-60. PubMed ID: 23228378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756).
    Calleris G; Rouprêt M; Seisen T; Bendjeddou L; Chevallier T; Masson-Lecomte A; Thibault C; Neuzillet Y; Audenet F; Xylinas E; Houédé N
    World J Urol; 2023 Dec; 41(12):3413-3420. PubMed ID: 37698632
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
    Aziz A; Dobruch J; Hendricksen K; Kluth LA; Necchi A; Noon A; Rink M; Roghmann F; Seiler R; Gontero P; Kassouf W; Shariat SF; Xylinas E;
    World J Urol; 2017 Sep; 35(9):1401-1407. PubMed ID: 28074261
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
    Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
    Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
    Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J
    Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    Rieken M; Schubert T; Xylinas E; Kluth L; Rouprêt M; Trinh QD; Lee RK; Al Hussein Al Awamlh B; Fajkovic H; Novara G; Margulis V; Lotan Y; Martinez-Salamanca JI; Matsumoto K; Seitz C; Remzi M; Karakiewicz PI; Scherr DS; Briganti A; Bachmann A; Shariat SF;
    Eur J Surg Oncol; 2014 Dec; 40(12):1693-9. PubMed ID: 24780094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.